The UK and US have announced a significant bilateral deal that will guarantee no import taxes on British medicine exports being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has agreed to boost spending on drugs through the public health system. This pledge secures that tariffs on these vital goods will stay at nothing for a duration of three years.
This agreement follows previous warnings to dramatically increase import taxes on patented pharmaceutical products, with increases mentioned as high as double the cost.
"This agreement between the Britain reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. drug exports," an announcement declared.
Commercial Significance
Medicines are one of the the United Kingdom's biggest exports to the America, which is easily the largest market for major UK drugmakers.
Statistics reveal that in the one-year period to the end of September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that timeframe.
"This deal protects work, boosts funding and paves the way for the UK to become a international leader for biotech and pharma," a minister remarked.
Key British Pledges
The deal includes several specific pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to double overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be restricted at 15%. In the past, repayments exceeded twenty percent.
Broader Context
The deal takes place against a protracted tension between the drug companies and the British authorities over drug pricing and approval rates.
This friction were heightened by assertions that US patients were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while substantial expansions have been announced toward projects in the United States.
One official acknowledged that the NHS had to increase expenditure on medicines, noting that its spending on drugs had decreased as a proportion of its total funding over the last ten years.
